IUIris Unterberger

Iris Unterberger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iris Unterberger has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Age- and sex- related characteristics in people with post-stroke epilepsy: initial presentation, stroke features, and mortality

    by Luisa Delazer, Lucie Buergi, Lukas Scherer, Kurt Moelgg, Anel Karisik, Walter Unterberger, Benjamin Dejakum, Silvia Felicetti, Christian Boehme, Christine Eckhardt, et al.

  • Open Access

    Lacosamide Safety During Pregnancy and Breastfeeding: A Single-Centre Experience and Comprehensive Narrative Review

    by Kamila Saramak, Manuela Kaml, Marina Peball, Luisa Delazer, Gerald Walser, Anna Hussl, Iris Unterberger, Alexandra Astner-Rohracher

    (1) Background: The management of epilepsy during pregnancy requires balancing effective seizure control against potential teratogenic effects of antiseizure medications (ASMs). Data on the safety of lacosamide (LCM), a third-generation ASM, during pregnancy and breastfeeding are limited. (2) Methods: To evaluate the safety and efficacy of LCM during pregnancy and breastfeeding, we report a single-centre case series and provide a comprehensive narrative review of the literature. (3) Results: In total, 22 cases of maternal exposure to LCM throughout pregnancy (1 monotherapy, 21 polytherapy) were identified, resulting in 21 live births (95.5%). Congenital malformations (atrial septal defect) were observed in one offspring exposed to LCM and levetiracetam (4.8%). Twelve newborns were breastfed (57.1%) without neurodevelopmental delay after twelve months. The literature search identified 16 studies, overall reporting data on 627 pregnancies with LCM (236 monotherapy, 391 polytherapy). Among 632 available pregnancy outcomes (3 twin pregnancies and 1 triplet in the polytherapy group) the proportion of live births was 81.3% (514/632). Major congenital malformations were reported in 2.5% (6/236) with LCM monotherapy and 11.9% (47/396) with polytherapy. (4) Conclusions: According to the literature, no major safety concerns, especially in LCM monotherapy, and no specific malformations associated with LCM exposure were identified. Conclusions are limited by the heterogeneity of studies and the small number of monotherapy-exposed cases. Larger, prospective studies with longer follow-up are required.

  • Open Access

    Repeat Expansions with Small TTTCA Insertions in MARCHF6 Cause Familial Myoclonus without Epilepsy

    by Theresa Kühnel, Elsa Leitão, Renate Lunzer, Fabian Kilpert, Sabine Kaya, Claudia Del Gamba, Kelly Astudillo, Steven Frucht, Marion Simonetta‐Moreau, Eric Bieth, et al.

    Background: Familial adult myoclonus epilepsy (FAME) is a rare autosomal dominant disorder caused by the same intronic TTTTA/TTTCA repeat expansion in seven distinct genes. TTTTA‐only expansions are benign, whereas those containing TTTCA insertions are pathogenic.Objective: We investigated the genetic basis of dominant cortical myoclonus without seizures in two unrelated families.Methods: Repeat‐primed polymerase chain reaction (PCR), long‐range PCR, and nanopore sequencing were used to detect and characterize expansions at known FAME loci.Results: We identified a novel repeat expansion in MARCHF6, comprising 388 to 454 elongated TTTTA repeats and 5 to 11 TTTCA repeats at the 3′‐terminus, segregating with cortical myoclonus in 8 affected individuals. This configuration shows meiotic stability but low‐level somatic variability in blood. We observed an inverse correlation between the number of TTTCA repeats and the age at myoclonus onset.Conclusions: These findings indicate that as little as five TTTCA repeats combined with expanded TTTTA repeats can cause cortical myoclonus without epilepsy, highlighting the potential mechanisms underlying FAME pathophysiology. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Staged treatment response in status epilepticus: Lessons from the SENSE registry

    by Isabelle Beuchat, Jan Novy, Felix Rosenow, Christoph Kellinghaus, Stephan Rüegg, Christian Tilz, Eugen Trinka, Iris Unterberger, Zeljko Uzelac, Adam Strzelczyk, et al.

    Objectives: Although in epilepsy patients the likelihood of becoming seizure‐free decreases substantially with each unsuccessful treatment, to our knowledge this has been poorly investigated in status epilepticus (SE). We aimed to evaluate the proportion of SE cessation and functional outcome after successive treatment steps.Methods: We conducted a post hoc analysis of a prospective, observational, multicenter cohort (Sustained Effort Network for treatment of Status Epilepticus [SENSE]), in which 1049 incident adult SE episodes were prospectively recorded at nine European centers. We analyzed 996 SE episodes without coma induction before the third treatment step. Rates of SE cessation, mortality (in ongoing SE or after SE control), and favorable functional outcome (assessed with modified Rankin scale) were evaluated after each step.Results: SE was treated successfully in 838 patients (84.1%), 147 (14.8%) had a fatal outcome (36% of them died while still in SE), and 11 patients were transferred to palliative care while still in SE. Patients were treated with a median of three treatment steps (range 1–13), with 540 (54.2%) receiving more than two steps (refractory SE [RSE]) and 95 (9.5%) more than five steps. SE was controlled after the first two steps in 45%, with an additional 21% treated after the third, and 14% after the fourth step. Likelihood of SE cessation (p < 0.001), survival (p = 0.003), and reaching good functional outcome (p < 0.001) decreased significantly between the first two treatment lines and the third, especially in patients not experiencing generalized convulsive SE, but remained relatively stable afterwards.Significance: The significant worsening of SE prognosis after the second step clinically supports the concept of RSE. However, and differing from findings in human epilepsy, RSE remains treatable in about one third of patients, even after several failed treatment steps. Clinical judgment remains essential to determine the aggressiveness and duration of SE treatment, and to avoid premature treatment cessation in patients with SE.


  • Open Access

    New-Onset Refractory Status Epilepticus Due to a Novel MT-TF Variant

    by Elisabetta Indelicato, Johannes Pfeilstetter, Michael Zech, Iris Unterberger, Julia Wanschitz, Steffen Berweck, Sylvia Boesch

    Objective The gene MT-TF encodes the mitochondrial tRNA of phenylalanine (tRNAphe). Its variations have been described as extremely rare etiologies of a variety of mitochondrial phenotypes. Methods By means of whole-exome sequencing (WES), we detected a novel likely causative MT-TF variant (m.610T>C) in a family presenting with a combined movement disorder and epilepsy phenotype. The variant was present at 97% heteroplasmy in the peripheral blood and in a homoplasmic state in skin fibroblast-derived DNA. Results The inaugural manifestation in the index patient was new-onset refractory myoclonic status epilepticus (NORSE) at the age of 29 years. Her son presented later with developmental regression and myoclonic epilepsy. On the beginning of valproate because of ongoing myoclonic seizures, the index patient developed a generalized brain edema requiring bilateral craniotomy. In the course of the disease, epileptic manifestations abated, and both patients developed a severe movement disorder phenotype with prominent spastic-dystonic features. Both patients did not display any further sign of mitochondrial disease. Discussion Our report expands the clinicogenetic background of tRNAphe disease spectrum and highlights pitfalls in the diagnostics and management of mitochondrial epilepsy. The present findings advocate the introduction of rapid genetic testing in the diagnostic flow chart of NORSE in adults.


  • Refractory Status Epilepticus

    by Isabelle Beuchat, Felix Rosenow, Christoph Kellinghaus, Eugen Trinka, Iris Unterberger, Stephan Rüegg, Raoul Sutter, Christian Tilz, Zeljko Uzelac, Andrea O. Rossetti, et al.

    Background and objectives: Refractory status epilepticus (RSE) bear significant morbidity and mortality. Therapy escalation and in some cases intubation are recommended. Most existing studies are retrospective and focus on ICUs. We aimed to describe routine-care management, and analyze determinants of RSE development and outcomes in a large multicenter cohort. Methods: We performed post hoc analysis of an observational, cohort study, who prospectively registered all consecutive adults with SE at 9 centers from 3 German-speaking countries. Only incident episodes were included. Ongoing SE despite 2 anti-seizure medications was defined as RSE. Patients intubated during first- or second-line treatments were excluded. Variables investigated included demographics, severity (Status Epilepticus Severity Score), etiology, and guideline-compliant treatment (defined as fixed minimum doses). Outcome parameters included survival and mRS at baseline and discharge (good: 0–2 or absence of worsening compared with pre-hospitalization). Results: Among 1179 SE episodes from 1049 adults, 996 patients were eligible (median age: 70 years, 52% female), of which 545 (54.7%) developed RSE. RSE was associated with higher baseline mRS (p<0.001) and treatment deviation from guidelines (p<0.001, OR 0.09; 95%CI 0.06-0.1). Good outcomes were observed in 52.7% of refractory patients, correlating with lower status epilepticus severity (p<0.001), absence of acute etiology (p<0.001, OR 0.5 95%CI 0.3-0.7), adequate first-line benzodiazepine dose (p<0.001, OR 2.5 95%CI 1.6-4.0), shorter durations of SE and hospitalization (both p<0.001), and lack of intubation (p<0.001, OR 0.4 95%CI 0.3-0.6). Most (71.7%) refractory patients were not intubated. Intubation was associated with younger age (p=0.006), more severe consciousness disturbances (p<0.001, OR 3.2 95%CI 2.1-4.8), more severe SE types (p<0.001), higher severity score (p=0.009), acute etiologies (p=0.01, OR 1.6 95%CI 1.1-2.4), more anti-seizure medications (p<0.001), initial treatment after shorter latency (p=0.01), worse outcomes (p<0.001, OR 0.4 95%CI 0.4-0.6), and longer hospitalizations (p<0.001). Discussion: Variables associated with RSE were identified, some potentially preventable. More than 70% of RSE were treated without intubation, suggesting that focal RSE without deep impairment of consciousness, in older patients, may be successfully treated outside ICUs. Trial Registration: Original cohort study registered at the German Clinical Trials Register (DRKS00000725).


  • Epileptic aphasia – A critical appraisal

    by Iris Unterberger, Eugen Trinka, Gerhard Ransmayr, Christoph Scherfler, Gerhard Bauer


  • The role of cortisol in trust behavior: Results from an experimental study on healthy controls and patients with juvenile myoclonic epilepsy

    by Andrija Javor, Laura Zamarian, Gerhard Ransmayr, Manuela Prieschl, Melanie Bergmann, Gerald Walser, Gerhard Luef, Wolfgang Prokop, Margarete Delazer, Iris Unterberger


  • Repetitive miniature spikes – An underreported EEG pattern

    by Iris Unterberger, Peter W. Kaplan, Gerhard Luef, Eugen Trinka, Gerald Walser, Gerhard Bauer


  • A further case of familial ring chromosome 20 mosaicism - molecular characterization of the ring and review of the literature

    by Iris Unterberger, Judith Dobesberger, Harald Schober, Birgit Krabichler, Claudia Lamina, Ulrich Schatz, Johannes Zschocke, Gerhard Luef, Dieter Kotzot, Christine Fauth